English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Gliomas have substantial mortality to incidence rate ratio and a dismal clinical course. Newer molecular insights, therefore, are imperative to refine glioma diagnosis, prognosis and therapy. Meningioma 1 ( MN1 ) gene is a transcriptional co-regulator implicated in other malignancies, albeit its significance in glioma pathology remains to be explored.  IGFBP5  is regulated transcriptionally by MN1 and IGF1 and is associated with higher glioma grade and shorter survival time, prompting us to ascertain their correlation in these tumors. We quantified the expression of  MN1 ,  IGFBP5  and  IGF1  in 40 glioma samples and examined their interrelatedness.  MN1  mRNA-protein inter-correlation and the gene’s copy number were evaluated in these tumors. Publicly available TCGA datasets were used to examine the association of  MN1  expression levels with patient survival and for validating our findings. We observed  MN1  overexpression correlated with low-grade (LGGs) and not high-grade gliomas and is not determined by the copy number alteration of the gene. Notably, gliomas with upregulated  MN1  have better overall survival (OS) and progression-free survival (PFS).  IGFBP5  expression associated inversely with  MN1  expression levels in gliomas but correlated positively with  IGF1  expression in only LGGs. This suggests a potential grade-specific interplay between repressive and activating roles of MN1 and IGF1, respectively, in the regulation of  IGFBP5 . Thus,  MN1  overexpression, a promising predictor of OS and PFS in gliomas, may serve as a prognostic biomarker in clinical practice to categorize patients with survival advantage.

MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients